Stockreport

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia [Yahoo! Finance]

Syndax Pharmaceuticals, Inc.  (SNDX) 
Last syndax pharmaceuticals, inc. earnings: 3/3 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.syndax.com
PDF WALTHAM, Mass. March 26, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of can [Read more]